Is Nutex Health, Inc. overvalued or undervalued?

As of 17 October 2025, the valuation grade for Nutex Health, Inc. moved from attractive to very attractive, indicating a strong improvement in its valuation outlook. The company appears to be undervalued, supported by a P/E ratio of 5, an EV to EBITDA ratio of 2.82, and an impressive ROCE of 128.63%. In comparison to peers, Nutex Health's EV to EBITDA ratio is significantly lower than Talkspace, Inc. at -344.3683 and Fulgent Genetics, Inc. at -8.0743, suggesting a more favorable valuation relative to its industry.
Nutex Health has demonstrated remarkable stock performance, with a year-to-date return of 199.26% compared to the S&P 500's 13.30%, and an astounding 3-year return of 10,965.93% versus the S&P 500's 81.19%. This performance reinforces the narrative that the stock is undervalued in the current market context.